Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
prednisone 1 nephrologydiseasesdrugs
tacrolimus 7 nephrologydiseasesdrugs
chronic kidney disease 10 nephrologydiseases
cyclosporine 6 nephrologydiseasesdrugs
glomerulonephritis 1 nephrologydiseases
mycophenolate mofetil 1 nephrologydiseasesdrugs
mycophenolic acid 1 nephrologydiseasesdrugs
prednisolone 1 nephrologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cyclosporine 19032 hepatic CYP3A4 enzymes [[31],[32]]. Therefore, dose adjustment of common immunosuppressive agents like cyclosporine and tacrolimus is usually not required. However, serum levels of immunosuppressive agents need to be
cyclosporine 19304 combined use of Ritonavir-bossted protease inhibitor Paritaprevir, dose adjustment of tacrolimus and cyclosporine is required. Due to prolonged blood serum level duration of tacrolimus (7-fold higher) and cyclosporine
cyclosporine 19408 cyclosporine is required. Due to prolonged blood serum level duration of tacrolimus (7-fold higher) and cyclosporine (3-fold higher) under 3D-therapy regimen, dose adjustment is required depending on tacrolimus or ciclosporin
cyclosporine 25441 liver or renal transplant-Currently taking an immunosuppressant regimen based on either tacrolimus or cyclosporine . Corticosteroids such as prednisone or prednisolone are permitted as components of the immunosuppressant
cyclosporine 37783 demonstrating promising results in this patient cohort. Simeprevir should not be administered with cyclosporine . Safety and tolerability were reported to be good with only few grade 3–4 adverse events.Based on
cyclosporine 40104 interactions caused by ritonavir. Therefore, levels of immunosuppressive agents (such as tacrolimus or cyclosporine ) have to be monitored closely and dose adjustments should be considered during therapy with such a booster
mycophenolate mofetil 38363 sirolimus and everolimus inhibitors and Ledipasvir. Additionally, no data for the interaction-potential for mycophenolate mofetil , mycophenolic acid, or azathioprine and Ledipasvir exist but it is expected that Ledipasvir and Sofosbuvir
mycophenolic acid 38386 inhibitors and Ledipasvir. Additionally, no data for the interaction-potential for mycophenolate mofetil, mycophenolic acid , or azathioprine and Ledipasvir exist but it is expected that Ledipasvir and Sofosbuvir do not have
prednisolone 25493 immunosuppressant regimen based on either tacrolimus or cyclosporine. Corticosteroids such as prednisone or prednisolone are permitted as components of the immunosuppressant regimen providing the dose is not more than 10
prednisone 25479 taking an immunosuppressant regimen based on either tacrolimus or cyclosporine. Corticosteroids such as prednisone or prednisolone are permitted as components of the immunosuppressant regimen providing the dose is not
tacrolimus 19049 enzymes [[31],[32]]. Therefore, dose adjustment of common immunosuppressive agents like cyclosporine and tacrolimus is usually not required. However, serum levels of immunosuppressive agents need to be closely monitored
tacrolimus 19289 treatment. In case of combined use of Ritonavir-bossted protease inhibitor Paritaprevir, dose adjustment of tacrolimus and cyclosporine is required. Due to prolonged blood serum level duration of tacrolimus (7-fold higher)
tacrolimus 19377 adjustment of tacrolimus and cyclosporine is required. Due to prolonged blood serum level duration of tacrolimus (7-fold higher) and cyclosporine (3-fold higher) under 3D-therapy regimen, dose adjustment is required
tacrolimus 19504 and cyclosporine (3-fold higher) under 3D-therapy regimen, dose adjustment is required depending on tacrolimus or ciclosporin trough levels.3. Patients with Decompensated Liver CirrhosisThe main target of anti-viral
tacrolimus 25427 pre or post liver or renal transplant-Currently taking an immunosuppressant regimen based on either tacrolimus or cyclosporine. Corticosteroids such as prednisone or prednisolone are permitted as components of the
tacrolimus 26330 liver transplant-Treatment-naive or experienced adults-Stable immunosuppressant regimen with either tacrolimus or ciclosporin-Metavir-Score F1–F4-HBV or HIV co-infection-Evidence of acute or chronic hepatic decompensation
tacrolimus 40090 given to drug interactions caused by ritonavir. Therefore, levels of immunosuppressive agents (such as tacrolimus or cyclosporine) have to be monitored closely and dose adjustments should be considered during therapy
Select Disease Character Offset Disease Term Instance
chronic kidney disease 1081 comprise HCV in patients with decompensated liver disease (Child-Pugh Class B or C), patients with chronic kidney disease , and patients on waiting lists to renal/liver transplantation or those with HCV recurrence after liver
chronic kidney disease 3594 commonly associated with advanced renal disease. High prevalence of HCV infection in patients with chronic kidney disease has been associated with increased morbidity and mortality in these patients. Therefore, HCV screening
chronic kidney disease 3747 increased morbidity and mortality in these patients. Therefore, HCV screening of patients suffering from chronic kidney disease before starting hemodialysis or consideration for transplantation is recommended.Until now, only few
chronic kidney disease 4683 performed by looking for the search terms hepatitis C, HCV, renal insufficiency, renal impairment, chronic kidney disease , liver cirrhosis, end stage liver disease and liver transplantation. Only English studies from 1995
chronic kidney disease 10892 result of accelerated atherosclerosis promoted by HCV [[5],[6]]. However, the mechanisms leading to chronic kidney disease in chronically HCV-infected patients are still unclear. Nevertheless, chronic HCV infection worldwide
chronic kidney disease 11064 unclear. Nevertheless, chronic HCV infection worldwide occurs in 20%–25% of patients suffering from chronic kidney disease . Furthermore, HCV infection is also associated with an increased morbidity and mortality in kidney transplant
chronic kidney disease 14169 below <8 g/dL. Preliminary pharmacokinetic data show mean Ctrough values of DAAs with stage 4 and 5 chronic kidney disease comparable to those without renal impairment, suggesting a good safety profile.No final data are available
chronic kidney disease 15878 cases, thus holding potential for a further treatment option in HCV genotype 1 infected patients with chronic kidney disease .ijms-16-18033-t002_Table 2Table 2SVR4 and SVR12 rates of HCV treatment in CKD stages 4/5 according to
chronic kidney disease 41758 reduced in these patients.Despite the lack of data concerning antiviral treatment in patients with chronic kidney disease , the EASL [[37]] has already taken up this issue suggesting antiviral treatment in chronic kidney disease,
chronic kidney disease 41864 chronic kidney disease, the EASL [[37]] has already taken up this issue suggesting antiviral treatment in chronic kidney disease , particularly those who are suitable candidates for renal transplantation. Until more data are available,
glomerulonephritis 10232 discussed in the literature. The most common HCV-associated nephropathy is type 1 membrano-proliferative glomerulonephritis . Another manifestation is type II mixed cryoglobulinemia, which is related to HCV-containing immune

You must be authorized to submit a review.